Therapeutic strategies to target multiple kinases in glioblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 700-711

  Sathornsumetee, Sith ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Combination; Glioblastoma; Kinase; Multitargeted kinase inhibitor; Polypharmacology; Small molecule inhibitor; Targeted therapy

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ABELSON KINASE; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; DACOMITINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; IMATINIB; INSULIN RECEPTOR; JANUS KINASE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; XL 184;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMORADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TUMOR; GENE MUTATION; GENE TRANSLOCATION; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; TREATMENT INDICATION;

EID: 80053521874     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378661     Document Type: Article

References (116)

1. Wen, P. Y.; Kesari, S., Malignant gliomas in adults. N. Engl. J. Med., 2008, 359 (5), 492-507.
2. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352 (10), 987-996.
3. Ballman, K. V.; Buckner, J. C.; Brown, P. D.; Giannini, C.; Flynn, P. J.; LaPlant, B. R.; Jaeckle, K. A., The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol., 2007, 9 (1), 29-38.
4. Lamborn, K. R.; Yung, W. K.; Chang, S. M.; Wen, P. Y.; Cloughesy, T. F.; DeAngelis, L. M.; Robins, H. I.; Lieberman, F. S.; Fine, H. A.; Fink, K. L.; Junck, L.; Abrey, L.; Gilbert, M. R.; Mehta, M.; Kuhn, J. G.; Aldape, K. D.; Hibberts, J.; Peterson, P. M.; Prados, M. D., Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol., 2008, 10 (2), 162-170.
5. Huse, J. T.; Holland, E. C., Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer, 2010, 10 (5), 319-331.
6. Van Meir, E. G.; Hadjipanayis, C. G.; Norden, A. D.; Shu, H. K.; Wen, P. Y.; Olson, J. J., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA. Cancer J. Clin., 2010, 60 (3), 166-193.
7. Furnari, F. B.; Fenton, T.; Bachoo, R. M.; Mukasa, A.; Stommel, J. M.; Stegh, A.; Hahn, W. C.; Ligon, K. L.; Louis, D. N.; Brennan, C.; Chin, L.; DePinho, R. A.; Cavenee, W. K., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev., 2007, 21 (21), 2683-2710.
8. Lemmon, M. A.; Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 2010, 141 (7), 1117-1134.
9. Chi, A. S.; Wen, P. Y., Inhibiting kinases in malignant gliomas. Expert Opin. Ther. Targets, 2007, 11 (4), 473-496.
10. Hanahan, D.; Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
11. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455 (7216), 1061-1068.
12. Mir, S. E.; De Witt Hamer, P. C.; Krawczyk, P. M.; Balaj, L.; Claes, A.; Niers, J. M.; Van Tilborg, A. A.; Zwinderman, A. H.; Geerts, D.; Kaspers, G. J.; Peter Vandertop, W.; Cloos, J.; Tannous, B. A.; Wesseling, P.; Aten, J. A.; Noske, D. P.; Van Noorden, C. J.; Wurdinger, T., In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010, 18 (3), 244-257.
13. Michaud, K.; Solomon, D. A.; Oermann, E.; Kim, J. S.; Zhong, W. Z.; Prados, M. D.; Ozawa, T.; James, C. D.; Waldman, T., Pharmacologic inhibition of cyclindependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res., 2010, 70 (8), 3228-3238.
14. Bergers, G.; Song, S., The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol., 2005, 7 (4), 452-464.
15. Hau, P.; Jachimczak, P.; Bogdahn, U., Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev. Anticancer Ther., 2009, 9 (11), 1663-1674.
16. Guo, D.; Wang, B.; Han, F.; Lei, T., RNA interference therapy for glioblastoma. Expert Opin. Biol. Ther., 2010, 10 (6), 927-936.
17. Zhang, J.; Yang, P. L.; Gray, N. S., Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9 (1), 28-39.
18. Bleau, A. M.; Huse, J. T.; Holland, E. C., The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8 (18), 2936-2944.
19. Gerber, D. E.; Laterra, J., Emerging monoclonal antibody therapies for malignant gliomas. Expert Opin. Investig. Drugs, 2007, 16 (4), 477-494.
20. Mathupala, S. P.; Guthikonda, M.; Sloan, A. E., RNAi based approaches to the treatment of malignant glioma. Technol. Cancer Res. Treat., 2006, 5 (3), 261-269.
21. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344 (14), 1031-1037.
22. Sathornsumetee, S.; Reardon, D. A.; Desjardins, A.; Quinn, J. A.; Vredenburgh, J. J.; Rich, J. N., Molecularly targeted therapy for malignant glioma. Cancer, 2007, 110 (1), 13-24.
23. Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H.; Chute, D. J.; Riggs, B. L.; Horvath, S.; Liau, L. M.; Cavenee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med., 2005, 353 (19), 2012-2024.
24. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L.; DePinho, R. A., Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318 (5848), 287-290.
25. Xu, A. M.; Huang, P. H., Receptor tyrosine kinase coactivation networks in cancer. Cancer Res., 2010, 70 (10), 3857-3860.
26. Gossage, L.; Eisen, T., Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res., 2010, 16 (7), 1973-1978.
27. Knight, Z. A.; Lin, H.; Shokat, K. M., Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer, 2010, 10 (2), 130-137.
28. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M., Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med., 2007, 356 (2), 125-134.
29. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J., Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359 (4), 378-390.
30. Hopkins, A. L., Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4 (11), 682-690.
31. Kerkela, R.; Grazette, L.; Yacobi, R.; Iliescu, C.; Patten, R.; Beahm, C.; Walters, B.; Shevtsov, S.; Pesant, S.; Clubb, F. J.; Rosenzweig, A.; Salomon, R. N.; Van Etten, R. A.; Alroy, J.; Durand, J. B.; Force, T., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med., 2006, 12 (8), 908-916.
32. Chu, T. F.; Rupnick, M. A.; Kerkela, R.; Dallabrida, S. M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Morgan, J. A.; Harris, D. M.; Ismail, N. S.; Chen, J. H.; Schoen, F. J.; Van den Abbeele, A. D.; Demetri, G. D.; Force, T.; Chen, M. H., Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370 (9604), 2011-2019.
33. Kilic, T.; Alberta, J. A.; Zdunek, P. R.; Acar, M.; Iannarelli, P.; O'Reilly, T.; Buchdunger, E.; Black, P. M.; Stiles, C. D., Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res., 2000, 60 (18), 5143-5150.
34. Wen, P. Y.; Yung, W. K.; Lamborn, K. R.; Dahia, P. L.; Wang, Y.; Peng, B.; Abrey, L. E.; Raizer, J.; Cloughesy, T. F.; Fink, K.; Gilbert, M.; Chang, S.; Junck, L.; Schiff, D.; Lieberman, F.; Fine, H. A.; Mehta, M.; Robins, H. I.; DeAngelis, L. M.; Groves, M. D.; Puduvalli, V. K.; Levin, V.; Conrad, C.; Maher, E. A.; Aldape, K.; Hayes, M.; Letvak, L.; Egorin, M. J.; Capdeville, R.; Kaplan, R.; Murgo, A. J.; Stiles, C.; Prados, M. D., Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res., 2006, 12 (16), 4899-4907
35. Raymond, E.; Brandes, A. A.; Dittrich, C.; Fumoleau, P.; Coudert, B.; Clement, P. M.; Frenay, M.; Rampling, R.; Stupp, R.; Kros, J. M.; Heinrich, M. C.; Gorlia, T.; Lacombe, D.; van den Bent, M. J., Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol., 2008, 26 (28), 4659-4665.
36. Razis, E.; Selviaridis, P.; Labropoulos, S.; Norris, J. L.; Zhu, M. J.; Song, D. D.; Kalebic, T.; Torrens, M.; Kalogera-Fountzila, A.; Karkavelas, G.; Karanastasi, S.; Fletcher, J. A.; Fountzilas, G., Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin. Cancer Res., 2009, 15 (19), 6258-6266.
37. Ziegler, D. S.; Wright, R. D.; Kesari, S.; Lemieux, M. E.; Tran, M. A.; Jain, M.; Zawel, L.; Kung, A. L., Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J. Clin. Invest., 2008, 118 (9), 3109-3122.
38. Reardon, D. A.; Egorin, M. J.; Quinn, J. A.; Rich, J. N.; Gururangan, S.; Vredenburgh, J. J.; Desjardins, A.; Sathornsumetee, S.; Provenzale, J. M.; Herndon, J. E., 2nd; Dowell, J. M.; Badruddoja, M. A.; McLendon, R. E.; Lagattuta, T. F.; Kicielinski, K. P.; Dresemann, G.; Sampson, J. H.; Friedman, A. H.; Salvado, A. J.; Friedman, H. S., Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol., 2005, 23 (36), 9359-9368.
39. Reardon, D. A.; Dresemann, G.; Taillibert, S.; Campone, M.; van den Bent, M.; Clement, P.; Blomquist, E.; Gordower, L.; Schultz, H.; Raizer, J.; Hau, P.; Easaw, J.; Gil, M.; Tonn, J.; Gijtenbeek, A.; Schlegel, U.; Bergstrom, P.; Green, S.; Weir, A.; Nikolova, Z., Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer, 2009, 101 (12), 1995-2004.
40. Dresemann, G.; Weller, M.; Rosenthal, M. A.; Wedding, U.; Wagner, W.; Engel, E.; Heinrich, B.; Mayer-Steinacker, R.; Karup-Hansen, A.; Fluge, O.; Nowak, A.; Mehdorn, M.; Schleyer, E.; Krex, D.; Olver, I. N.; Steinbach, J. P.; Hosius, C.; Sieder, C.; Sorenson, G.; Parker, R.; Nikolova, Z., Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol., 2010, 96 (3), 393-402.
41. Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Sathornsumetee, S.; Rich, J. N.; Quinn, J. A.; Lagattuta, T. F.; Egorin, M. J.; Gururangan, S.; McLendon, R.; Herndon, J. E., 2nd; Friedman, A. H.; Salvado, A. J.; Friedman, H. S., Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol., 2008, 10 (3), 330-340.
42. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E., Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov., 2007, 6 (9), 734-745.
43. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356 (2), 115-124.
44. Demetri, G. D.; van Oosterom, A. T.; Garrett, C. R.; Blackstein, M. E.; Shah, M. H.; Verweij, J.; McArthur, G.; Judson, I. R.; Heinrich, M. C.; Morgan, J. A.; Desai, J.; Fletcher, C. D.; George, S.; Bello, C. L.; Huang, X.; Baum, C. M.; Casali, P. G., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368 (9544), 1329-1338.
45. de Bouard, S.; Herlin, P.; Christensen, J. G.; Lemoisson, E.; Gauduchon, P.; Raymond, E.; Guillamo, J. S., Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol., 2007, 9 (4), 412-423.
46. Schueneman, A. J.; Himmelfarb, E.; Geng, L.; Tan, J.; Donnelly, E.; Mendel, D.; McMahon, G.; Hallahan, D. E., SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res., 2003, 63 (14), 4009-4016.
47. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell., 2009, 15 (3), 220-231.
48. Friedman, H. S.; Vredenburgh, J. J.; Desjardins, A.; Janney, D. E.; Peters, K. B.; Friedman, A. H.; Gururangan, S.; Reardon, D. A., A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J. Clin. Oncol., 2009, 27 (suppl), abstr e13024.
49. Chahal, M.; Xu, Y.; Lesniak, D.; Graham, K.; Famulski, K.; Christensen, J. G.; Aghi, M.; Jacques, A.; Murray, D.; Sabri, S.; Abdulkarim, B., MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol., 2010, 12 (8), 822-833.
50. Basto, D.; Trovisco, V.; Lopes, J. M.; Martins, A.; Pardal, F.; Soares, P.; Reis, R. M., Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol., 2005, 109 (2), 207-210.
51. Sathornsumetee, S.; Hjelmeland, A. B.; Keir, S. T.; McLendon, R. E.; Batt, D.; Ramsey, T.; Yusuff, N.; Rasheed, B. K.; Kieran, M. W.; Laforme, A.; Bigner, D. D.; Friedman, H. S.; Rich, J. N., AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res., 2006, 66 (17), 8722-8730
52. Siegelin, M. D.; Raskett, C. M.; Gilbert, C. A.; Ross, A. H.; Altieri, D. C., Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci. Lett., 2010, 478 (3), 165-170.
53. Sheng, Z.; Li, L.; Zhu, L. J.; Smith, T. W.; Demers, A.; Ross, A. H.; Moser, R. P.; Green, M. R., A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat. Med., 2010, 16 (6), 671-677.
54. Reardon, D. A.; Vredenburgh, J. J.; Desjardins, A.; Peters, K.; Gururangan, S.; Sampson, J. H.; Marcello, J.; Herndon, J. E.,; McLendon, R. E.; Janney, D.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S., Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J. Neurooncol., 2010, 101 (1), 57-66.
55. Hainsworth, J. D.; Ervin, T.; Friedman, E.; Priego, V.; Murphy, P. B.; Clark, B. L.; Lamar, R. E., Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the firstline treatment of patients with glioblastoma multiforme. Cancer, 2010, 116 (15), 3663-3669.
56. Brandsma, D.; Stalpers, L.; Taal, W.; Sminia, P.; van den Bent, M. J., Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol., 2008, 9 (5), 453-461.
57. Nabors, L. B.; Rosenfeld, M.; Chamberlain, M.; Phuphanich, S.; Batchelor, T.; Supko, S.; Desideri, S.; Xiaobu, Y.; Wright, J.; Grossman, S., A phase I trial of sorafenib (BAY43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). J. Clin. Oncol., 2007, 25 (18s), abstr 2058.
58. Wen, P. Y.; Cloughesy, T.; Kuhn, J.; Lamborn, K.; Abrey, L. E.; Lieberman, F.; Robins, H. I.; Wright, J.; Prados, M. D.; Gilbert, M., Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J. Clin. Oncol., 2009, 27 (15s), abstr 2006.
59. Sathornsumetee, S.; Rich, J. N., Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) 2006, 42 (10), 657-70.
60. Haas-Kogan, D. A.; Prados, M. D.; Tihan, T.; Eberhard, D. A.; Jelluma, N.; Arvold, N. D.; Baumber, R.; Lamborn, K. R.; Kapadia, A.; Malec, M.; Berger, M. S.; Stokoe, D., Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst., 2005, 97 (12), 880-887.
61. Nicholas, M. K.; Lukas, R. V.; Jafri, N. F.; Faoro, L.; Salgia, R., Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res., 2006, 12 (24), 7261-7270.
62. Guillamo, J. S.; de Bouard, S.; Valable, S.; Marteau, L.; Leuraud, P.; Marie, Y.; Poupon, M. F.; Parienti, J. J.; Raymond, E.; Peschanski, M., Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin. Cancer Res., 2009, 15 (11), 3697-3704.
63. Rich, J. N.; Sathornsumetee, S.; Keir, S. T.; Kieran, M. W.; Laforme, A.; Kaipainen, A.; McLendon, R. E.; Graner, M. W.; Rasheed, B. K.; Wang, L.; Reardon, D. A.; Ryan, A. J.; Wheeler, C.; Dimery, I.; Bigner, D. D.; Friedman, H. S., ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res., 2005, 11 (22), 8145-8157.
64. Damiano, V.; Melisi, D.; Bianco, C.; Raben, D.; Caputo, R.; Fontanini, G.; Bianco, R.; Ryan, A.; Bianco, A. R.; De Placido, S.; Ciardiello, F.; Tortora, G., Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin. Cancer Res., 2005, 11 (15), 5639-5644.
65. Mcnicol, K. A.; Kreisl, T. N.; Iwamoto, F. M.; Sul, J.; Fine, H. A., Phase I/II study of vandetanib for patients with recurrent malignant gliomas. J. Clin. Oncol., 2010, 28 (15s), abstr 2083.
66. Brickhouse, A.; Vredenburgh, J. J.; Gururangan, S.; Reardon, D. A.; Desjardins, A.; Peters, K.; Herndon, J. E.; Norfleet, J.; Marcello, J. E.; Friedman, H. S., Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). J. Clin. Oncol., 2010, 28 (15s), abstr 2038.
67. Drappatz, J.; Norden, A. D.; Wong, E. T.; Doherty, L. M.; Lafrankie, D. C.; Ciampa, A.; Kesari, S.; Sceppa, C.; Gerard, M.; Phan, P.; Schiff, D.; Batchelor, T. T.; Ligon, K. L.; Young, G.; Muzikansky, A.; Weiss, S. E.; Wen, P. Y., Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys., 2010, 78 (1), 85-90.
68. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D., Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2006, 355 (26), 2733-2743.
69. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L., A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res., 2004, 64 (18), 6652-6659.
70. Frentzas, S. N.; Groves, M. D.; Barriuso, J.; Harris, D.; Reardon, D.; Curtis, M. C.; Suttle, A. B.; Ma, B.; Lager, J. J.; de Bono, J. S., Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J. Clin. Oncol., 2009, 27 (suppl), abstr 2040.
71. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 2006, 354 (24), 2531-2541.
72. de Groot, J.; Milano, V., Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J. Neurooncol., 2009, 95 (2), 151-163.
73. Du, J.; Bernasconi, P.; Clauser, K. R.; Mani, D. R.; Finn, S. P.; Beroukhim, R.; Burns, M.; Julian, B.; Peng, X. P.; Hieronymus, H.; Maglathlin, R. L.; Lewis, T. A.; Liau, L. M.; Nghiemphu, P.; Mellinghoff, I. K.; Louis, D. N.; Loda, M.; Carr, S. A.; Kung, A. L.; Golub, T. R., Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol., 2009, 27 (1), 77-83.
74. Lu, K. V.; Zhu, S.; Cvrljevic, A.; Huang, T. T.; Sarkaria, S.; Ahkavan, D.; Dang, J.; Dinca, E. B.; Plaisier, S. B.; Oderberg, I.; Lee, Y.; Chen, Z.; Caldwell, J. S.; Xie, Y.; Loo, J. A.; Seligson, D.; Chakravari, A.; Lee, F. Y.; Weinmann, R.; Cloughesy, T. F.; Nelson, S. F.; Bergers, G.; Graeber, T.; Furnari, F. B.; James, C. D.; Cavenee, W. K.; Johns, T. G.; Mischel, P. S., Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res., 2009, 69 (17), 6889-6898.
75. Milano, V.; Piao, Y.; LaFortune, T.; de Groot, J., Dasatinibinduced autophagy is enhanced in combination with temozolomide in glioma. Mol. Cancer Ther., 2009, 8 (2), 394-406.
76. Abounader, R.; Laterra, J., Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol., 2005, 7 (4), 436-451.
77. Huang, P. H.; Mukasa, A.; Bonavia, R.; Flynn, R. A.; Brewer, Z. E.; Cavenee, W. K.; Furnari, F. B.; White, F. M., Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U S A., 2007, 104 (31), 12867-12872.
78. Jun, H. T.; Sun, J.; Rex, K.; Radinsky, R.; Kendall, R.; Coxon, A.; Burgess, T. L., AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res., 2007, 13 (22 Pt 1), 6735-6742.
79. Tseng, J. R.; Kang, K. W.; Dandekar, M.; Yaghoubi, S.; Lee, J. H.; Christensen, J. G.; Muir, S.; Vincent, P. W.; Michaud, N. R.; Gambhir, S. S., Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J. Nucl. Med., 2008, 49 (1), 129-134.
80. Wen, P. Y.; Prados, M.; Schiff, D.; Reardon, D. A.; Cloughesy, T.; Mikkelsen, T.; Batchelor, T.; Drappatz, J.; Chamberlain, M. C.; De Groot, J. F., Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR-2, and RET, in patients (pts) with progressive glioblastoma (GB). J. Clin. Oncol., 2010, 28 (15s), abstr 2006.
81. Gonzales, A. J.; Hook, K. E.; Althaus, I. W.; Ellis, P. A.; Trachet, E.; Delaney, A. M.; Harvey, P. J.; Ellis, T. A.; Amato, D. M.; Nelson, J. M.; Fry, D. W.; Zhu, T.; Loi, C. M.; Fakhoury, S. A.; Schlosser, K. M.; Sexton, K. E.; Winters, R. T.; Reed, J. E.; Bridges, A. J.; Lettiere, D. J.; Baker, D. A.; Yang, J.; Lee, H. T.; Tecle, H.; Vincent, P. W., Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible panerbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther., 2008, 7 (7), 1880-1889.
82. Fan, Q. W.; Knight, Z. A.; Goldenberg, D. D.; Yu, W.; Mostov, K. E.; Stokoe, D.; Shokat, K. M.; Weiss, W. A., A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell., 2006, 9 (5), 341-349.
83. Dancey, J. E.; Chen, H. X., Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 2006, 5 (8), 649-659.
84. Rodon, J.; Perez, J.; Kurzrock, R., Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist., 2010, 15 (1), 37-50.
85. Storniolo, A. M.; Pegram, M. D.; Overmoyer, B.; Silverman, P.; Peacock, N. W.; Jones, S. F.; Loftiss, J.; Arya, N.; Koch, K. M.; Paul, E.; Pandite, L.; Fleming, R. A.; Lebowitz, P. F.; Ho, P. T.; Burris, H. A., Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol., 2008, 26 (20), 3317-3323.
86. Goudar, R. K.; Shi, Q.; Hjelmeland, M. D.; Keir, S. T.; McLendon, R. E.; Wikstrand, C. J.; Reese, E. D.; Conrad, C. A.; Traxler, P.; Lane, H. A.; Reardon, D. A.; Cavenee, W. K.; Wang, X. F.; Bigner, D. D.; Friedman, H. S.; Rich, J. N., Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther., 2005, 4 (1), 101-112.
87. Wang, M. Y.; Lu, K. V.; Zhu, S.; Dia, E. Q.; Vivanco, I.; Shackleford, G. M.; Cavenee, W. K.; Mellinghoff, I. K.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S., Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTENintact glioblastoma cells. Cancer Res., 2006, 66 (16), 7864-7869.
88. Reardon, D. A.; Quinn, J. A.; Vredenburgh, J. J.; Gururangan, S.; Friedman, A. H.; Desjardins, A.; Sathornsumetee, S.; Herndon, J. E., Dowell, J. M.; McLendon, R. E.; Provenzale, J. M.; Sampson, J. H.; Smith, R. P.; Swaisland, A. J.; Ochs, J. S.; Lyons, P.; Tourt-Uhlig, S.; Bigner, D. D.; Friedman, H. S.; Rich, J. N., Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res., 2006, 12 (3 Pt 1), 860-868.
89. Kreisl, T. N.; Lassman, A. B.; Mischel, P. S.; Rosen, N.; Scher, H. I.; Teruya-Feldstein, J.; Shaffer, D.; Lis, E.; Abrey, L. E., A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol., 2009, 92 (1), 99-105.
90. Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Gururangan, S.; Friedman, A. H.; Herndon, J. E., 2nd; Marcello, J.; Norfleet, J. A.; McLendon, R. E.; Sampson, J. H.; Friedman, H. S., Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol., 2010, 96 (2), 219-230.
91. Chang, S. M.; Kuhn, J.; Lamborn, K.; Cloughesy, T.; Robins, I.; Lieberman, F.; Yung, A.; Dancey, J.; Prados, M.; Wen, P., Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J. Clin. Oncol., 2009, 27 (15s), abstr 2004.
92. Hjelmeland, A. B.; Lattimore, K. P.; Fee, B. E.; Shi, Q.; Wickman, S.; Keir, S. T.; Hjelmeland, M. D.; Batt, D.; Bigner, D. D.; Friedman, H. S.; Rich, J. N., The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol. Cancer Ther., 2007, 6 (9), 2449-2457.
93. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest., 2008, 118 (9), 3065-3074.
94. Tonra, J. R.; Deevi, D. S.; Corcoran, E.; Li, H.; Wang, S.; Carrick, F. E.; Hicklin, D. J., Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res., 2006, 12 (7 Pt 1), 2197-2207.
95. Reardon, D. A.; Egorin, M. J.; Desjardins, A.; Vredenburgh, J. J.; Beumer, J. H.; Lagattuta, T. F.; Gururangan, S.; Herndon, J. E.,; Salvado, A. J.; Friedman, H. S., Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, 115 (10), 2188-2198.
96. Hasselbalch, B.; Lassen, U.; Hansen, S.; Holmberg, M.; Sorensen, M.; Kosteljanetz, M.; Broholm, H.; Stockhausen, M. T.; Poulsen, H. S., Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol., 2010, 12 (5), 508-516.
97. Sathornsumetee, S.; Desjardins, A.; Vredenburgh, J. J.; McLendon, R. E.; Marcello, J.; Herndon, J. E.; Mathe, A.; Hamilton, M.; Rich, J. N.; Norfleet, J. A.; Gururangan, S.; Friedman, H. S.; Reardon, D. A., Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol., 2010, 12 (12), 1300-1310.
98. Shah, N. P.; Kasap, C.; Weier, C.; Balbas, M.; Nicoll, J. M.; Bleickardt, E.; Nicaise, C.; Sawyers, C. L., Transient potent BCRABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell, 2008, 14 (6), 485-493;
99. Chien, A. J.; Illi, J. A.; Ko, A. H.; Korn, W. M.; Fong, L.; Chen, L. M.; Kashani-Sabet, M.; Ryan, C. J.; Rosenberg, J. E.; Dubey, S.; Small, E. J.; Jahan, T. M.; Hylton, N. M.; Yeh, B. M.; Huang, Y.; Koch, K. M.; Moasser, M. M., A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin. Cancer Res., 2009, 15 (17), 5569-5575.
100. Dudek, A. Z.; Zolnierek, J.; Dham, A.; Lindgren, B. R.; Szczylik, C., Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 2009, 115 (1), 61-67.
101. Holdhoff, M.; Supko, J. G.; Gallia, G. L.; Hann, C. L.; Bonekamp, D.; Ye, X.; Cao, B.; Olivi, A.; Grossman, S. A., Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol., 2010, 97 (2), 241-245.
102. Gilbert, M. R.; Gonzalez, J.; Hunter, K.; Hess, K.; Giglio, P.; Chang, E.; Puduvalli, V.; Groves, M. D.; Colman, H.; Conrad, C.; Levin, V.; Woo, S.; Mahajan, A.; de Groot, J.; Yung, W. K., A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol., 2010, 12 (11), 1167-1172.
103. Kamoun, W. S.; Ley, C. D.; Farrar, C. T.; Duyverman, A. M.; Lahdenranta, J.; Lacorre, D. A.; Batchelor, T. T.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Fukumura, D.; Sorensen, A. G.; Jain, R. K., Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol., 2009, 27 (15), 2542-2552.
104. Batchelor, T. T.; Sorensen, A. G.; di Tomaso, E.; Zhang, W. T.; Duda, D. G.; Cohen, K. S.; Kozak, K. R.; Cahill, D. P.; Chen, P. J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M. M.; Plotkin, S.; Drappatz, J.; Louis, D. N.; Ivy, P.; Scadden, D. T.; Benner, T.; Loeffler, J. S.; Wen, P. Y.; Jain, R. K., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11 (1), 83-95.
105. van den Bent, M. J.; Vogelbaum, M. A.; Wen, P. Y.; Macdonald, D. R.; Chang, S. M., End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J. Clin. Oncol., 2009, 27 (18), 2905-2908.
106. Wen, P. Y.; Macdonald, D. R.; Reardon, D. A.; Cloughesy, T. F.; Sorensen, A. G.; Galanis, E.; Degroot, J.; Wick, W.; Gilbert, M. R.; Lassman, A. B.; Tsien, C.; Mikkelsen, T.; Wong, E. T.; Chamberlain, M. C.; Stupp, R.; Lamborn, K. R.; Vogelbaum, M. A.; van den Bent, M. J.; Chang, S. M., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol., 2010, 28 (11), 1963-1972.
107. Dhermain, F. G.; Hau, P.; Lanfermann, H.; Jacobs, A. H.; van den Bent, M. J., Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol., 2010, 9 (9), 906-920.
108. Sathornsumetee, S.; Cao, Y.; Marcello, J. E.; Herndon, J. E., McLendon, R. E.; Desjardins, A.; Friedman, H. S.; Dewhirst, M. W.; Vredenburgh, J. J.; Rich, J. N., Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol., 2008, 26 (2), 271-278.
109. Chen, W.; Delaloye, S.; Silverman, D. H.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.; Phelps, M. E.; Cloughesy, T., Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol., 2007, 25 (30), 4714-4721.
110. Tolmachev, V.; Stone-Elander, S.; Orlova, A., Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol., 2010, 11 (10), 992-1000.
111. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B., Identification of human brain tumour initiating cells. Nature, 2004, 432 (7015), 396-401.
112. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444 (7120), 756-760.
113. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A. B.; Shi, Q.; McLendon, R. E.; Bigner, D. D.; Rich, J. N., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 2006, 66 (16), 7843-7848.
114. Bao, S.; Wu, Q.; Li, Z.; Sathornsumetee, S.; Wang, H.; McLendon, R. E.; Hjelmeland, A. B.; Rich, J. N., Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res., 2008, 68 (15), 6043-6048.
115. Li, Z.; Bao, S.; Wu, Q.; Wang, H.; Eyler, C.; Sathornsumetee, S.; Shi, Q.; Cao, Y.; Lathia, J.; McLendon, R. E.; Hjelmeland, A. B.; Rich, J. N., Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 2009, 15 (6), 501-513.
116. Li, Z.; Wang, H.; Eyler, C. E.; Hjelmeland, A. B.; Rich, J. N., Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J. Biol. Chem., 2009, 284 (25), 16705-16709.